CervoMed (CRVO) Projected to Post Earnings on Friday

CervoMed (NASDAQ:CRVO) is expected to be releasing its earnings data before the market opens on Friday, April 4th. Analysts expect CervoMed to post earnings of ($0.67) per share and revenue of $1.79 million for the quarter.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The company had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $1.51 million. On average, analysts expect CervoMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CervoMed Stock Performance

CRVO stock opened at $13.58 on Thursday. The company has a market capitalization of $118.19 million, a PE ratio of -6.69 and a beta of 1.84. The company’s fifty day moving average price is $4.52 and its 200-day moving average price is $7.47. CervoMed has a one year low of $1.80 and a one year high of $25.92.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CRVO. Roth Mkm increased their target price on CervoMed from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, March 18th. Morgan Stanley reiterated an “underweight” rating on shares of CervoMed in a research report on Wednesday, December 11th. Chardan Capital upgraded shares of CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Thursday, March 13th. HC Wainwright downgraded shares of CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. Finally, Jones Trading raised CervoMed from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Thursday, March 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.